CON Quote, Financials, Valuation and Earnings

Kindly MD has a net margin of 4.63% compared to Concentra Group Holdings Parent's net margin of -156.54%. Concentra Group Holdings Parent's return on equity of 23.06% beat Kindly MD's return on equity of -201.03%.

Concentra Group Holdings Parent has a consensus price target of $27.88, signalling upside risk potential of 28.46%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that Concentra Group Holdings Parent has higher upside potential than Kindly MD, analysts believe Concentra Group Holdings Parent is more attractive than Kindly MD.

Concentra Group Holdings Parent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Concentra Group Holdings Parent has a quarterly dividend of $0.06 per share corresponding to a yield of 0%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concentra Group Holdings Parent pays 926.87% of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend.

Concentra Group Holdings Parent quarterly revenues are $465M, which are larger than Kindly MD quarterly revenues of $647.9K. Concentra Group Holdings Parent's net income of $21.5M is higher than Kindly MD's net income of -$1M. Notably, Concentra Group Holdings Parent's price-to-earnings ratio is 17.66x while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concentra Group Holdings Parent is 1.43x versus 3.19x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of 4.63% compared to Concentra Group Holdings Parent's net margin of 6.07%. Concentra Group Holdings Parent's return on equity of 23.06% beat Pediatrix Medical Group's return on equity of -12.67%.

Concentra Group Holdings Parent has a consensus price target of $27.88, signalling upside risk potential of 28.46%. On the other hand Pediatrix Medical Group has an analysts' consensus of $18.36 which suggests that it could grow by 29.64%. Given that Pediatrix Medical Group has higher upside potential than Concentra Group Holdings Parent, analysts believe Pediatrix Medical Group is more attractive than Concentra Group Holdings Parent.

Concentra Group Holdings Parent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.485, suggesting its more volatile than the S&P 500 by 48.547%.

Concentra Group Holdings Parent has a quarterly dividend of $0.06 per share corresponding to a yield of 0%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concentra Group Holdings Parent pays 926.87% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend.

Concentra Group Holdings Parent quarterly revenues are $465M, which are smaller than Pediatrix Medical Group quarterly revenues of $502.4M. Concentra Group Holdings Parent's net income of $21.5M is lower than Pediatrix Medical Group's net income of $30.5M. Notably, Concentra Group Holdings Parent's price-to-earnings ratio is 17.66x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concentra Group Holdings Parent is 1.43x versus 0.59x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 4.63% compared to Concentra Group Holdings Parent's net margin of -13.15%. Concentra Group Holdings Parent's return on equity of 23.06% beat The Oncology Institute's return on equity of -220.55%.

Concentra Group Holdings Parent has a consensus price target of $27.88, signalling upside risk potential of 28.46%. On the other hand The Oncology Institute has an analysts' consensus of -- which suggests that it could grow by 75.44%. Given that The Oncology Institute has higher upside potential than Concentra Group Holdings Parent, analysts believe The Oncology Institute is more attractive than Concentra Group Holdings Parent.

Concentra Group Holdings Parent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Concentra Group Holdings Parent has a quarterly dividend of $0.06 per share corresponding to a yield of 0%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Concentra Group Holdings Parent pays 926.87% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend.

Concentra Group Holdings Parent quarterly revenues are $465M, which are larger than The Oncology Institute quarterly revenues of $100.3M. Concentra Group Holdings Parent's net income of $21.5M is higher than The Oncology Institute's net income of -$13.2M. Notably, Concentra Group Holdings Parent's price-to-earnings ratio is 17.66x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concentra Group Holdings Parent is 1.43x versus 0.22x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 4.63% compared to Concentra Group Holdings Parent's net margin of 4.12%. Concentra Group Holdings Parent's return on equity of 23.06% beat US Physical Therapy's return on equity of 3.86%.

Concentra Group Holdings Parent has a consensus price target of $27.88, signalling upside risk potential of 28.46%. On the other hand US Physical Therapy has an analysts' consensus of $108.33 which suggests that it could grow by 50.61%. Given that US Physical Therapy has higher upside potential than Concentra Group Holdings Parent, analysts believe US Physical Therapy is more attractive than Concentra Group Holdings Parent.

Concentra Group Holdings Parent has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.507, suggesting its more volatile than the S&P 500 by 50.722%.

Concentra Group Holdings Parent has a quarterly dividend of $0.06 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.46% to investors and pays a quarterly dividend of $0.45 per share. Concentra Group Holdings Parent pays 926.87% of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Concentra Group Holdings Parent quarterly revenues are $465M, which are larger than US Physical Therapy quarterly revenues of $180.4M. Concentra Group Holdings Parent's net income of $21.5M is higher than US Physical Therapy's net income of $7.4M. Notably, Concentra Group Holdings Parent's price-to-earnings ratio is 17.66x while US Physical Therapy's PE ratio is 39.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Concentra Group Holdings Parent is 1.43x versus 1.61x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.